|
L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)—A single-arm phase II study. |
|
|
Honoraria - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen |
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen |
Research Funding - Merck; Pharmacyclics |
|
|
Honoraria - Gilead Sciences; Janssen; Roche; SERVIER |
Consulting or Advisory Role - Janssen; Sandoz; SERVIER |
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen; Roche |
|
|
Consulting or Advisory Role - MorphoSys; Sandoz-Novartis |
Research Funding - Abbvie; AstraZeneca; Bayer; Celltrion; Gilead Sciences; Janssen; Merck; MorphoSys; Roche; Sandoz-Novartis; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen |
Speakers' Bureau - Gilead Sciences; Janssen; Roche |
Research Funding - Abbvie; Celgene |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Takeda |
Research Funding - Celgene; Roche |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Takeda |
Research Funding - Celgene |
|
|
|
Consulting or Advisory Role - Celgene; MorphoSys |
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Gilead Sciences; Janssen; Mundipharma; Roche/Genentech; SERVIER |
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Novartis; NOvimmune; Roche/Genentech |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |